Joseph S, et al. - In a large contemporary cohort of boys with Duchenne muscular dystrophy (DMD) in the UK and in relation to glucocorticoid (GC) regimen, researchers determined the fracture burden and growth impairment. The rate of fracture incidence was at least four times higher than in healthy boys in this analysis of 832 boys with DMD (2006 to 2015) in the UK NorthStar database. In those treated with daily deflazacort, at 1,367 per 10,000 person-years, the highest rate of fracture incidence was observed. Investigators found that the highest incidence rate of fracture and the greatest degree of linear growth failure was seen in boys treated with daily deflazacort. There is an pressing need for bone-protective therapies and strategies to improve linear growth.